The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | J | Antiinfectives for systemic use | |
2 | J01 | Antibacterials for systemic use | |
3 | J01G | Aminoglycoside antibacterials | |
4 | J01GB | Other aminoglycosides |
Code | Title | |
---|---|---|
J01GB01 | Tobramycin | |
J01GB03 | Gentamicin | |
J01GB04 | Kanamycin | |
J01GB05 | Neomycin | |
J01GB06 | Amikacin | |
J01GB07 | Netilmicin | |
J01GB08 | Sisomicin | |
J01GB09 | Dibekacin | |
J01GB10 | Ribostamycin | |
J01GB11 | Isepamicin | |
J01GB12 | Arbekacin | |
J01GB13 | Bekanamycin | |
J01GB14 |
Active Ingredient | Description | |
---|---|---|
Amikacin |
Amikacin is an antibiotic used for a number of bacterial infections. Amikacin works by blocking the function of the bacteria’s 30S ribosomal subunit, making it unable to produce proteins. |
|
Gentamicin |
Gentamicin is usually bactericidal in action. Although the exact mechanism of action has not been fully elucidated, the drug appears to inhibit protein synthesis in susceptible bacteria by irreversibly binding to 30S ribosomal subunits. |
|
Kanamycin |
Kanamycin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. |
|
Neomycin |
Neomycin is an aminoglycoside antibiotic and acts by binding to polysomes, inhibiting protein synthesis and generating errors in the transcription of the genetic code. |
|
Netilmicin |
|
|
Plazomicin |
Plazomicin is an aminoglycoside antibacterial. It is used for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible microorganism(s): Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae. |
|
Sisomicin |
|
|
Tobramycin |
Tobramycin is an aminoglycoside antibiotic produced by Streptomyces tenebrarius. It acts primarily by disrupting protein synthesis leading to altered cell membrane permeability, progressive disruption of the cell envelope and eventual cell death. It is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations. |
Title | Information Source | Document Type | |
---|---|---|---|
AMIKIN INJECTION Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ARIKAYCE Inhalation suspension | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
GENTAMICIN Eye / Ear drops | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
GENTAMICIN Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
NIVEMYCIN Tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
SELEMYCIN Solution for injection/infusion | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
TOBI Podhaler Inhalation powder, hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
TOBRAMYCIN Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
TYMBRINEB Nebuliser solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |